These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 9597374)
1. Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. Carlsen SM; Grill V; Følling I Diabetes Res Clin Pract; 1998 Jan; 39(1):47-54. PubMed ID: 9597374 [TBL] [Abstract][Full Text] [Related]
3. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Freemark M; Bursey D Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776 [TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563 [TBL] [Abstract][Full Text] [Related]
5. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Chazova I; Almazov VA; Shlyakhto E Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753 [TBL] [Abstract][Full Text] [Related]
6. Metformin in the treatment of obesity in subjects with normal glucose tolerance. Tankova T; Dakovska L; Kirilov G; Koev D Rom J Intern Med; 2003; 41(3):269-75. PubMed ID: 15526510 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. DeFronzo RA; Barzilai N; Simonson DC J Clin Endocrinol Metab; 1991 Dec; 73(6):1294-301. PubMed ID: 1955512 [TBL] [Abstract][Full Text] [Related]
8. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815 [TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093 [TBL] [Abstract][Full Text] [Related]
10. A refined-JinQi-JiangTang tablet ameliorates prediabetes by reducing insulin resistance and improving beta cell function in mice. Gao LH; Liu Q; Liu SN; Chen ZY; Li CN; Lei L; Sun SJ; Li LY; Liu JL; Shen ZF J Ethnopharmacol; 2014; 151(1):675-85. PubMed ID: 24286962 [TBL] [Abstract][Full Text] [Related]
11. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799 [TBL] [Abstract][Full Text] [Related]
13. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. Arslanian SA; Lewy V; Danadian K; Saad R J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157 [TBL] [Abstract][Full Text] [Related]
15. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. James AP; Watts GF; Mamo JC Diabetes Obes Metab; 2005 Jul; 7(4):381-9. PubMed ID: 15955124 [TBL] [Abstract][Full Text] [Related]
16. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. Worsley R; Jane F; Robinson PJ; Bell RJ; Davis SR Climacteric; 2015 Apr; 18(2):270-7. PubMed ID: 25333776 [TBL] [Abstract][Full Text] [Related]
17. Metformin in obesity associated with antipsychotic drug administration: a pilot study. Baptista T; Hernàndez L; Prieto LA; Boyero EC; de Mendoza S J Clin Psychiatry; 2001 Aug; 62(8):653-5. PubMed ID: 11561940 [No Abstract] [Full Text] [Related]
18. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. Kulshreshtha B; Gupta N; Ganie MA; Ammini AC Gynecol Endocrinol; 2012 Oct; 28(10):823-6. PubMed ID: 22475072 [TBL] [Abstract][Full Text] [Related]
19. Can metformin reduce insulin resistance in polycystic ovary syndrome? Açbay O; Gündoğdu S Fertil Steril; 1996 May; 65(5):946-9. PubMed ID: 8612854 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]